IndiPharm (M) Awarded Bionexus Status by Malaysian Biotechnology Corporation
July 27 2015 - 10:50PM
Business Wire
IndiPharm (M) SDN BHD, a division of IndiPharm Inc. was awarded
BioNexus status from the Malaysian Biotechnology Corporation
(Biotechcorp) at BIO Philadelphia 2015, held on June 15-18,
2015.
IndiPharm is a Clinical Development Organization, headquartered
in the United States, with clinical and administrative operations
in Malaysia and India. IndiPharm’s experienced management team,
U.S.-based client services, strong global SOPs, well-trained
medical professional staff, and deep understanding of local culture
and regulatory systems, facilitates the delivery of high-quality
clinical trials with lower costs, faster recruitment, and better
quality outcomes.
Biotechcorp is an agency under the purview of Ministry of
Science, Technology and Innovation (MOSTI), and is owned by the
Ministry of Finance Incorporated & Federal Lands Commissioner.
It is governed by the National Bioeconomy Council and advised by
the Biotechnology International Advisory Panel, both chaired by the
Honorable Prime Minister of Malaysia. Biotechcorp is responsible
for executing the objectives of the National Biotechnology Policy
(NBP) by identifying value propositions in both R&D and
commerce, and supporting these ventures via financial assistance
and developmental services.
BioNexus is a special status awarded to qualified international
and Malaysian companies undertaking value-added biotechnology
and/or life sciences activities. The status endows fiscal
incentives, grants, and other guarantees to assist growth.
Dato’ Dr. Mohd. Nazlee Kamal, Chief Executive Officer of
Malaysian Biotechnology Corporation said, “We are very pleased for
IndiPharm to join the list of BioNexus status companies, especially
as they have chosen to establish their Asian headquarters in
Malaysia. IndiPharm’s vast knowledge and expertise in clinical
research services will undoubtedly enrich the growth of the
biomedical sector in Malaysia, particularly in conducting clinical
trials. We hope IndiPharm will take full advantage of the benefits
that the BioNexus status offers to contribute to the healthcare
community.”
IndiPharm Inc. has relocated its Asian operations center to
Kuala Lumpur in anticipation of future growth and client demands.
Edward Brennan MD, President and CEO of IndiPharm Inc. stated,
“IndiPharm is excited to have received the BioNexus status. Aside
from the financial incentives provided, the Bionexus status grants
IndiPharm access to clients and markets that otherwise would not be
possible. We look forward to a long and successful relationship
with Malaysian Biotechnology Corporation as we continue to expand
our presence in Malaysia and Asia.”
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150727006409/en/
IndiPharmJeffrey Scott Yablon,
+60326157870U.S.: +1-914-330-2860Vice President & General
Managerjyablon@indipharm.com